PRPF18

Across TCGA pan-cancer cohorts, PRPF18 RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of PRPF18’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where PRPF18 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types PRPF18 is over-expressed in tumor, although a few such as KICH and COAD show the opposite, repressed pattern.

LIHC, KICH, and COAD are the cancer types where PRPF18 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PRPF18 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Male	II,III,IV	+0.709	<.001	9	view →
KICH	Female	II,III,IV	−1.304	<.001	7	view →
COAD	Female	All	−0.669	.005	4	view →
STAD	All	All	+0.347	.001	4	view →
HNSC	All	All	+0.202	.023	4	view →
CHOL	All	All	+1.128	<.001	3	view →
BLCA	All	III,IV	+0.375	.013	3	view →
READ	All	All	−0.368	.005	2	view →
THCA	Female	All	−0.240	.016	2	view →
PRAD	All	All	−0.176	.042	2	view →
ESCA	All	All	+0.456	.022	1	view →
LUAD	Female	II,III,IV	−0.288	.036	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

PRPF18–LIHC

Open the LIHC breakdown →